Details for New Drug Application (NDA): 202387
✉ Email this page to a colleague
The generic ingredient in SITAGLIPTIN PHOSPHATE is sitagliptin phosphate. There are thirty-five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the sitagliptin phosphate profile page.
Summary for 202387
| Tradename: | SITAGLIPTIN PHOSPHATE |
| Applicant: | Sandoz |
| Ingredient: | sitagliptin phosphate |
| Patents: | 0 |
Pharmacology for NDA: 202387
| Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Medical Subject Heading (MeSH) Categories for 202387
Suppliers and Packaging for NDA: 202387
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SITAGLIPTIN PHOSPHATE | sitagliptin phosphate | TABLET;ORAL | 202387 | ANDA | Sandoz Inc | 0781-5766 | 0781-5766-31 | 30 TABLET, FILM COATED in 1 BOTTLE (0781-5766-31) |
| SITAGLIPTIN PHOSPHATE | sitagliptin phosphate | TABLET;ORAL | 202387 | ANDA | Sandoz Inc | 0781-5766 | 0781-5766-92 | 90 TABLET, FILM COATED in 1 BOTTLE (0781-5766-92) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 25MG BASE | ||||
| Approval Date: | Jan 14, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 50MG BASE | ||||
| Approval Date: | Jan 14, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Jan 14, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
